机构地区:[1]胶州市人民医院神经外科,山东省胶州266300 [2]胶州市人民医院中药制剂科,山东省胶州266300
出 处:《中国基层医药》2018年第9期1140-1144,共5页Chinese Journal of Primary Medicine and Pharmacy
摘 要:目的 利用大鼠动物模型研究中药制剂脑得康丸的毒理学作用.方法 将SD大鼠采用随机数字表法分为对照组、脑得康丸小剂量组(3.85 g/kg)、大剂量组(7.71 g/kg)和最大耐受剂量组(77.14 g/kg),每组20只,雌雄各半.脑得康丸各剂量组经口灌胃给药,对照组给予蒸馏水,各组持续给药12周,最大耐受剂量组给药1周.实验期间观察动物生存情况,检测给药末期大鼠血常规、血生化和脏器HE病理.结果各脑得康丸剂量组大鼠在实验期间无死亡,未见毒性反应,表现无异常,1~12周的体质量增长正常(F=0.688、0.540、0.121、0.065、0.128、0.239、0.199、0.378、0.127、0.446、0.906和0.665,P=0.562、0.585、0.886、0.937、0.880、0.788、0.820、0.687、0.881、0.642、0.410和0.518),雌性及雄性的红细胞(RBC)(♀:F=0.178,P=0.910,♂:F=0.119,P=0.948)、血红蛋白(HGB)(♀:F=0.046,P=0.987,♂:F=0.072,P=0.975)、红细胞比容(HCT)(♀:F=0.126,P=0.944,♂:F=0.054,P=0.983)、血小板(PLT)(♀:F=0.515,P=0.675,♂:F=0.500,P=0.685)、白细胞(WBC)(♀:F=0.078,P=0.972,♂:F=0.057,P=0.982)、嗜酸性粒细胞(Eos)(♀:F=0.078,P=0.972,♂:F=0.057,P=0.982)、淋巴细胞(Lym)(♀:F=0.078,P=0.972,♂:F=0.057,P=0.982)、中性粒细胞(Neu)(♀:F=0.134,P=0.939,♂:F=0.090,P=0.999)、丙氨酸氨基转换酶(ALT)(♀:F=0.572,P=0.637,♂:F=0.200,P=0.896)、门冬氨酸氨基转换酶(AST)(♀:F=0.572,P=0.637,♂:F=0.200,P=0.896)、总蛋白(TP)(♀:F=0.665,P=0.579,♂:F=0.343,P=0.795)、白蛋白(ALB)(♀:F=0.533,P=0.663,♂:F=0.668,P=0.577)、甘油三酯(TG)(♀:F=0.843,P=0.480,♂:F=0.561,P=0.644)、总胆固醇(CHOL)(♀:F=0.245,P=0.864,♂:F=0.046,P=0.987)、血糖(GLU)(♀:F=0.216,P=0.884,♂:F=0.095,P=0.963)、尿素氮(BUN)(♀:F=0.172,P=0.914,♂:F=0.203,P=0.894)和肌酐(Cr)(♀�Objective To study the toxicological effects of Nao - de - kang on rats. Methods According to the digital table ,SD rats were randomly divided into blank group and Nao- de- kang small dose group(3.85g/kg), high dose group(7.71g/kg) and maximum tolerated dose group(77. 14g/kg),20 rats in each group, half male and half female. All groups were treated for 12 weeks, and the maximum tolerated dose group was treated for 1 week. The animal activity during treatment, the blood routine indicators, blood biochemical index and the organs for pathological examination were recorded and compared. Results There was no mortality in the dose group of rats in the experimental period. The weights of 4 groups had no statistically significant differeuces during treatment ( F = 0. 688 ,0. 540,0.121, 0.065,0. 128,0. 239,0. 199,0. 378,0. 127,0. 446,0. 906 and 0. 665,P =0. 562,0. 585,0. 886,0. 937,0. 880, 0. 788,0. 820,0. 687,0.881,0. 642,0. 410 and 0. 518) ,male and femal's red blood cell(RBC) ( ♀ :F =0. 178 ,P = 0.910,♂:F=0.119,P=0.948),hemoglobin(HGB)( ♀ :F=0.046,P=0.987, ♂:F=0.072,P=0.975), hematokrit( HCT) ( ♀:F =0. 126,P =0, 944, ♂ :F =0. 054,P=0.983) ,platelet( PLT) (♀ :F =0. 515,P =0. 675, ♂:F = 0. 500, P = 0.685 ), white blood cell (WBC) ( ♀ : F = 0. 078, P = 0. 972, ♂: F = 0. 057, P = 0. 982), eosnophils(Eos) ( ♀ : F = 0. 078, P = 0. 972, ♂F = 0. 057, P = 0. 982 ), lymphocyte ( Lym ) ( ♀ : F = 0. 078, P = 0. 972, ♂ :F=0. 057,P =0. 982), neutrophilic granulocyte (Neu) ( ♀:F =0. 134,P =0. 939, ♂ :F =0. 090,P = 0. 999), alanine aminotransfease (ALT) ( ♀ : F = 0. 572, P = 0. 637, ♂: F = 0. 200, P = 0. 896 ), aspartate amin- otransferase(AST) ( ♀ :F =0.572,P =0. 637, ♂ :F = 0. 200,P =0. 896) ,total protein(TP) ( ♀ :F = 0. 665,P = 0. 579, ♂ :F =0. 343,P =0.795) ,albumin(ALB) ( ♂ :F =0. 533 ,P =0. 663, ♂ :F =0. 668,P =0. 577), tri
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...